
Top of the morning to you, and a fine one it is. Despite the gloomy, gray skies hovering over the Pharmalot campus, our spirits are as sunny as can be. After all, as the Morning Mayor once intoned, “Every new day should be unwrapped like a precious gift.” So while you tug on the ribbon, we will fire up the coffee kettle for another cup of stimulation. Our choice today is filled with the aroma of fresh blueberries. Please feel free to join us. Meanwhile, we have assembled the latest list of interesting items to help you get going. We hope your day is meaningful and productive. And, of course, do stay in touch. …
An ultra-conservative federal judge, appointed by former President Trump, is presiding over a closely watched case challenging regulatory approval of mifepristone — and if he sides with the anti-abortion groups that filed the lawsuit, the decision could potentially set a sweeping precedent that could undermine the infrastructure for evaluating all drugs, STAT explains. Some worry a ruling that undoes U.S. Food and Drug Administration approval of mifepristone could open the door to any third party challenging a class of medicines that might be politically unpopular — from Covid-19 vaccines and weight loss medications, to HIV pills and sickle cell treatments.
Charles River Laboratories, one of the largest clinical research organizations in the U.S., suspended shipments of non-human primates that are widely used in pharmaceutical research after receiving a subpoena from federal authorities probing a Cambodian smuggling ring, STAT says. The move comes after several people, including two Cambodian wildlife officials, were indicted in November for alleged involvement in the monkey-smuggling operation. The smugglers obtained long-tail macaques, which are protected by international law, from national parks and protected areas in Cambodia, and then shipped them with labels falsely identifying the primates as having been bred in captivity.
Create a display name to comment
This name will appear with your comment